Skip to Content
Merck
CN
All Photos(2)

Documents

Safety Information

CKT1MAG-97K

Millipore

MILLIPLEX® Canine Kidney Toxicity Expanded Magnetic Bead Panel 1, CKT1MAG-97K

The analytes available for this multiplex kit are: Clusterin, Cystatin C, Kidney Injury Molecule-1 (KIM-1), IL-8, Lipocalin-2/NGAL, MCP-1, Osteopontin (OPN).

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Quality Level

200

species reactivity

canine

manufacturer/tradename

Milliplex®

assay range

accuracy: 89-107%
sensitivity: 0.005-0.630 ng/mL
(All other analytes; MinDC +2SD)
sensitivity: 0.670 pg/mL
(KIM-1; MinDC +2SD)
standard curve range: 0.01-10 ng/mL
(Cystatin C)
standard curve range: 0.01-10 ng/mL
(Osteopontin)
standard curve range: 0.03-20 ng/mL
(Lipocalin-2/NGAL)
standard curve range: 0.07-50 ng/mL
(IL-8)
standard curve range: 0.07-50 ng/mL
(MCP-1)
standard curve range: 1.0-700 pg/mL
(KIM-1)
standard curve range: 1.4-1,000 ng/mL
(Clusterin)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

Related Categories

General description

As one of the leading causes of drug candidate attrition, toxicity research is receiving more attention, especially in the search of sensitive, organ-specific toxicity biomarkers. In pharmaceutical and chemical industries, the kidney is routinely assessed during toxicity evaluations. The importance of the kidney as a central detoxification organ leads to a high exposure of renal tissue to drugs, reactive metabolites, and environmental compounds. Traditional markers for assessing renal toxicity, such as blood urea nitrogen (BUN) and serum creatinine, are insensitive and non-specific. For improved, non-invasive detection of acute nephrotoxicity, a panel of novel urinary kidney biomarkers has been identified and verified for preclinical studies in relevant animal species. The MILLIPLEX® portfolio provides a valuable research assay to investigate multiple biomarkers of kidney injury in canine urine samples using the Luminex® xMAP® instrument platform.

The MILLIPLEX® Canine Kidney Toxicity Expanded Panel 1 is to be used for the simultaneous quantification of the following 7 analytes in any combination in canine urine samples: Clusterin, Cystatin C, Kidney Injury Molecule-1 (KIM-1), IL-8, Lipocalin-2/NGAL, MCP-1, and Osteopontin (OPN). This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls while can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Toxicity

Application

  • Analytes: Clusterin, Cystatin C, Kidney Injury Molecule-1 (KIM-1), IL-8, Lipocalin-2/NGAL, MCP-1, Osteopontin (OPN)
  • Recommended Sample Type: Canine urine
  • Recommended Sample Dilution: 25 μL of 1:2 diluted urine for normal subjects; optimal dilutions for disease subjects should be determined
  • Assay Run Time: Primary incubation of 2 hours, followed by a secondary incubation of 1 hour, both at room temperature (20-25°C)
  • Research Category: Toxicology

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Other Notes

Please contact Technical Service for linearity of dilution.
Sensitivity: See kit protocol for individual analytes sensitivities.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Target Organs

Respiratory Tract

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alvaro Felipe de Lima Ruy Dias et al.
Veterinary world, 13(8), 1620-1626 (2020-10-17)
Canine visceral leishmaniasis (CanL) has a broad spectrum of changes, with kidney disease being considered the main cause of mortality. Thus, this study aimed to monitor serum and urinary biomarkers in response to two short-term treatments for CanL. Thirty dogs

Related Content

Kidney Toxicity Multiplex Assays | MILLIPLEX®

Multiplex kidney toxicity assays detect nephrotoxicity biomarkers in small samples, minimizing time and costs for toxicity screening.

Multiplex Assays for Vet Med/Animal Health Research | MILLIPLEX® Assays

Discover benefits of using biomarker detection multiplex immunoassays for companion and agricultural animal health research and find vet med multiplex assays.

Multiplexing Tips & Tricks

UnEnhance research with MILLIPLEX® multiplexing tips, industry guidance, and one-day assays for limited lab time.

Multiplex Toxicity Assays | MILLIPLEX® Assays

Multiplex toxicity assays enable researchers to simultaneously measure multiple toxicity biomarkers of various organs to gain a better understanding of toxicity. Explore how MILLIPLEX® multiplex toxicity assays are advancing research on liver injury, kidney toxicity, genotoxicity, and more.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service